| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Portela |
| Other names | ZTS-00084768 |
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C6580H10118N1760O2038S46 |
| Molar mass | 147964.37 g·mol−1 |
Relfovetmab, sold under the brand namePortela, is a felinizedmonoclonal antibody for the alleviation of pain associated with osteoarthritis in cats.[3] Relfovetmab targetsnerve growth factor.[3] Nerve growth factor binds toTrkA receptors located on immune cells to elicit the release of additional proinflammatory mediators, including nerve growth factor itself.[2] These inflammatory mediators lead to further peripheral sensitization involved in pain perception.[2] The inhibition of nerve growth factor was demonstrated to provide relief from pain associated withosteoarthritis.[2]
Relfovetmab was authorized for veterinary use in the European Union in October 2025,[4] and in Canada in December 2025.[5]
Relfovetmab isindicated for the alleviation of pain associated with osteoarthritis in cats.[6]
In September 2025, theCommittee for Veterinary Medicinal Products of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Portela, solution for injection, intended for cats.[2] The applicant for this veterinary medicinal product is Zoetis Belgium.[2] Relfovetmab was authorized for veterinary use in the European Union in October 2025.[4]
Relfovetmab was authorized for veterinary use in Canada in December 2025.[5]
Relfovetmab is theinternational nonproprietary name.[7]
Relfovetmab is sold under the brand name Portela.[4][5]
